NDAORALSUSPENSION
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
BACTRIM (sulfamethoxazole; trimethoprim) by PharmaIN is clinical pharmacology bactrim is rapidly absorbed following oral administration. First approved in 1975.
Drug data last refreshed Just now · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTRIM is a fixed-dose combination antibiotic containing sulfamethoxazole and trimethoprim, used to treat bacterial infections including urinary tract infections, certain pneumonias, and other susceptible infections. The two components work synergistically by inhibiting sequential steps in bacterial folate synthesis, providing broad-spectrum activity. It is rapidly absorbed orally with peak blood levels occurring 1–4 hours after administration.
$0.002BPart D
LOE ApproachingDeclining brand in LOE phase with minimal Part D volume signals a small, consolidating team focused on lifecycle extension or transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY BACTRIM is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized in humans to at least 5…
Worked on BACTRIM at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.